Lehmann, P. and Huber, E. and Doerner, T. and Fleck, M. (2012) Macrophage activation syndrome. ZEITSCHRIFT FUR RHEUMATOLOGIE, 71 (8). pp. 701-706. ISSN 0340-1855, 1435-1250
Full text not available from this repository. (Request a copy)Abstract
Macrophage activation syndrome (MAS) is an infrequent but potentially life-threatening complication of various autoimmune diseases. It is characterized by excessive activation of macrophages induced by a dysfunction of the immune system, although the underlying abnormalities remain to be delineated. Sepsis-like symptoms accompanied by cytopenia, hepatosplenomegaly, coagulopathy and multiple organ dysfunctions are typical disease manifestations. Due to the lack of validated classification criteria and distinct laboratory markers, the diagnosis of MAS is often difficult to establish. However, early diagnosis and therapy is of utmost importance to ensure best possible outcome. Treatment regimens include high doses of glucocorticoids, classical immunosuppressive agents as well as novel biologics.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | JUVENILE IDIOPATHIC ARTHRITIS; ONSET STILLS-DISEASE; ACQUIRED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; KILLER-CELL DYSFUNCTION; OF-THE-LITERATURE; RHEUMATOID-ARTHRITIS; SOLUBLE CD163; ANAKINRA; TOCILIZUMAB; ETANERCEPT; Hemophagocytosis; Macrophage activation syndrome; Adult onset Still's disease; Systemic idiopathic juvenile arthritis; sCD163 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 May 2020 11:33 |
| Last Modified: | 05 May 2020 11:33 |
| URI: | https://pred.uni-regensburg.de/id/eprint/18039 |
Actions (login required)
 |
View Item |
